Scripps Tumorgraft Study
Completed
- Conditions
- Solid Tumor Malignancy or Hematologic Malignancy
- Registration Number
- NCT01726699
- Lead Sponsor
- Scripps Translational Science Institute
- Brief Summary
Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
- Age 21 or over
- diagnosis of a solid tumor malignancy, either resectable or metastatic or a hematologic malignancy
- cognitively and emotionally able to give informed consent
Exclusion Criteria
- Under age 21
- Not cognitively or emotionally able to give informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Facilitate the development of individualized tumorgraft models for many different types of cancer. 3 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets were identified in tumorgraft models from NCT01726699 for solid tumors and hematologic malignancies?
How do tumorgraft-derived biomarkers in NCT01726699 predict drug response compared to traditional xenograft models?
What adverse events are associated with tumorgraft-based preclinical drug testing in the Scripps Translational Science Institute trial?
Which drug classes or combination therapies were evaluated using tumorgrafts in NCT01726699 for cancer treatment?
How does the Scripps Tumorgraft Study advance personalized therapy for pancreatic cancer and lymphoma subtypes?
Trial Locations
- Locations (1)
Scripps Translational Science Institute
🇺🇸La Jolla, California, United States